NCT05338502View on ClinicalTrials.gov

Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 8, 2019

Primary Completion Date

September 3, 2019

Study Completion Date

September 3, 2019

Conditions
Healthy
Interventions
DRUG

Selpercatinib

Administered orally.

DRUG

Ranitidine

Administered orally.

DRUG

Omeprazole

Administered orally.

Trial Locations (1)

53704

Covance Clinical Research Unit, Inc., Madison

Sponsors

Collaborators (1)

Loxo Oncology, Inc.
All Listed Sponsors
collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT05338502 - Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants | Biotech Hunter | Biotech Hunter